AstraZeneca Says Drug Cocktail Effective Against COVID-19 in Late-Stage Study

The phase 3 trial preliminary results showed the drug cut the risk of developing severe COVID-19 or dying by 50 percent compared to a placebo in people who did not require hospitalization and had been showing symptoms for a week or less.